PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
EBIT growth similar to TRAW's 100.00%. Walter Schloss might infer both firms share similar operational efficiencies.
94.20%
Positive operating income growth while TRAW is negative. John Neff might view this as a competitive edge in operations.
94.81%
Positive net income growth while TRAW is negative. John Neff might see a big relative performance advantage.
98.22%
Positive EPS growth while TRAW is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
98.22%
Positive diluted EPS growth while TRAW is negative. John Neff might view this as a strong relative advantage in controlling dilution.
200.00%
Share count expansion well above TRAW's 129.98%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
200.00%
Diluted share count expanding well above TRAW's 129.98%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
12.59%
Positive OCF growth while TRAW is negative. John Neff would see this as a clear operational advantage vs. the competitor.
12.59%
Positive FCF growth while TRAW is negative. John Neff would see a strong competitive edge in net cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
66.67%
Under 50% of TRAW's 59775.48%. Michael Burry raises concerns about the firm’s ability to build intrinsic value relative to its rival.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
We cut SG&A while TRAW invests at 61301.60%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.